Browse by Clinical Topic:


Featured CME/CE Content:
 
neuroscienceCME Editors' Picks:



Managing the Patient with IBD Throughout Life: Best Practices in Transitional Care

Premiere Date: Tuesday, October 19, 2021

This activity offers CE credit for:

  1. ABIM (MOC)
  2. Medicine (accme)
  3. Nursing (ANCC)
  4. Pharmacy (acpe)
  5. PA (aapa)
  6. Other


All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Creditâ„¢

Credit Expiration Date:
Wednesday, October 19, 2022
Note: Credit Is No Longer Available

Faculty


Miguel Regueiro, MD, AGAF, FACG, FACPMiguel Regueiro, MD, AGAF, FACG, FACP (Moderator)
Chair, Digestive Disease and Surgery
Chair, Department of Gastroenterology, Hepatology, and Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Professor, Department of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland, OH

Jennifer Dotson, MD, MPHJennifer Dotson, MD, MPH 
Co-Director
The Center for Pediatric and Adolescent Inflammatory Bowel Disease
Associate Professor of Clinical Pediatrics
Division of Gastroenterology, Hepatology and Nutrition
The Ohio State University College of Medicine
Principle Investigator
Center for innovation in Pediatric Practice
Abigail Wexner Research Institute at Nationwide Children's Hospital
Columbus, OH

Jessica Philpott, MD, PhDJessica Philpott, MD, PhD 
Center for Inflammatory Bowel Disease
Department of Gastroenterology, Hepatology & Nutrition
Cleveland Clinic
Cleveland, OH

Statement of Need

Despite available guideline recommendations on primary health care management services that should be offered to patients with inflammatory bowel disease (IBD), preventive management such as immunizations and physical screenings in patients with IBD is suboptimal.

This CME Outfitters Live and OnDemand will feature expert faculty discussing recommended immunizations and preventive screenings for patients with IBD, along with best practices for clinicians to integrate them into their practice to improve health outcomes for their patients.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Initiate multidisciplinary collaboration to provide optimal care for children and adolescents as they transition to adult care.
  • Implement strategies to address disparities in care in patients with IBD by establishing trust, providing education, and engaging in shared decision-making (SDM).

Financial Support

Supported by educational grants from AbbVie Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

Gastroenterologists, PAs, nurse practitioners, nurses, dietitians, and pharmacists

Credit Information

ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Enduring material

Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Regueiro receives research support from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He receives unrestricted educational grants from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Salix Pharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is on advisory boards and consults for AbbVie Inc.; Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Miraca Laboratories; Pfizer Inc.; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.

Dr. Dotson receives grants and research support from the Crohn's and Colitis Foundation.

Dr. Philpott is on the speakers bureau for AbbVie Inc.

Michael Franks, APRN, AGACNP-BC, FNP-BC, (peer reviewer) has no disclosures to report.

Marlon (Tony) Graham, MD, (peer reviewer) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

TV-130-101921-90

Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download